IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc. (IDYA) Stock Competitors & Peer Comparison
See (IDYA) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IDYA | $32.60 | +0.00% | 2.9B | -25.59 | -$1.28 | N/A |
| VRTX | $458.05 | +0.00% | 115.3B | 29.66 | $15.31 | N/A |
| REGN | $737.45 | +0.00% | 76.1B | 17.69 | $41.44 | +0.49% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $311.10 | +0.00% | 41.4B | 133.91 | $2.33 | N/A |
| ARGX | $684.50 | +0.00% | 41.1B | 33.92 | $19.56 | N/A |
| INSM | $144.00 | +0.00% | 29.3B | -21.18 | -$6.42 | N/A |
| UTHR | $527.00 | +0.00% | 23B | 18.83 | $27.84 | N/A |
| BNTX | $89.31 | +0.00% | 22.4B | -16.60 | -$5.38 | N/A |
Stock Comparison
IDYA vs VRTX Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, VRTX has a market cap of 115.3B. Regarding current trading prices, IDYA is priced at $32.60, while VRTX trades at $458.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas VRTX's P/E ratio is 29.66. In terms of profitability, IDYA's ROE is -0.11%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, IDYA is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check VRTX's competition here
IDYA vs REGN Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, REGN has a market cap of 76.1B. Regarding current trading prices, IDYA is priced at $32.60, while REGN trades at $737.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas REGN's P/E ratio is 17.69. In terms of profitability, IDYA's ROE is -0.11%, compared to REGN's ROE of +0.15%. Regarding short-term risk, IDYA is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check REGN's competition here
IDYA vs VRNA Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, IDYA is priced at $32.60, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas VRNA's P/E ratio is -102.80. In terms of profitability, IDYA's ROE is -0.11%, compared to VRNA's ROE of -0.30%. Regarding short-term risk, IDYA is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check VRNA's competition here
IDYA vs SGEN Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, IDYA is priced at $32.60, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas SGEN's P/E ratio is -57.19. In terms of profitability, IDYA's ROE is -0.11%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, IDYA is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check SGEN's competition here
IDYA vs ALNY Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, ALNY has a market cap of 41.4B. Regarding current trading prices, IDYA is priced at $32.60, while ALNY trades at $311.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas ALNY's P/E ratio is 133.91. In terms of profitability, IDYA's ROE is -0.11%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, IDYA is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check ALNY's competition here
IDYA vs ARGX Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, ARGX has a market cap of 41.1B. Regarding current trading prices, IDYA is priced at $32.60, while ARGX trades at $684.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas ARGX's P/E ratio is 33.92. In terms of profitability, IDYA's ROE is -0.11%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, IDYA is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check ARGX's competition here
IDYA vs INSM Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, INSM has a market cap of 29.3B. Regarding current trading prices, IDYA is priced at $32.60, while INSM trades at $144.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas INSM's P/E ratio is -21.18. In terms of profitability, IDYA's ROE is -0.11%, compared to INSM's ROE of -1.68%. Regarding short-term risk, IDYA is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check INSM's competition here
IDYA vs UTHR Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, UTHR has a market cap of 23B. Regarding current trading prices, IDYA is priced at $32.60, while UTHR trades at $527.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas UTHR's P/E ratio is 18.83. In terms of profitability, IDYA's ROE is -0.11%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, IDYA is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check UTHR's competition here
IDYA vs BNTX Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, BNTX has a market cap of 22.4B. Regarding current trading prices, IDYA is priced at $32.60, while BNTX trades at $89.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas BNTX's P/E ratio is -16.60. In terms of profitability, IDYA's ROE is -0.11%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, IDYA is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check BNTX's competition here
IDYA vs MRNA Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, MRNA has a market cap of 20.3B. Regarding current trading prices, IDYA is priced at $32.60, while MRNA trades at $52.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas MRNA's P/E ratio is -7.08. In terms of profitability, IDYA's ROE is -0.11%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, IDYA is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check MRNA's competition here
IDYA vs BGNE Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, IDYA is priced at $32.60, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas BGNE's P/E ratio is -22.55. In terms of profitability, IDYA's ROE is -0.11%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, IDYA is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check BGNE's competition here
IDYA vs ROIV Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, ROIV has a market cap of 19.8B. Regarding current trading prices, IDYA is priced at $32.60, while ROIV trades at $27.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas ROIV's P/E ratio is -23.68. In terms of profitability, IDYA's ROE is -0.11%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, IDYA is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check ROIV's competition here
IDYA vs RPRX Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, RPRX has a market cap of 19.4B. Regarding current trading prices, IDYA is priced at $32.60, while RPRX trades at $45.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas RPRX's P/E ratio is 25.48. In terms of profitability, IDYA's ROE is -0.11%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, IDYA is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check RPRX's competition here
IDYA vs RVMD Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, RVMD has a market cap of 19B. Regarding current trading prices, IDYA is priced at $32.60, while RVMD trades at $99.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas RVMD's P/E ratio is -16.10. In terms of profitability, IDYA's ROE is -0.11%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, IDYA is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check RVMD's competition here
IDYA vs DNA-WT Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, IDYA is priced at $32.60, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, IDYA's ROE is -0.11%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, IDYA is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check DNA-WT's competition here
IDYA vs INCY Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, INCY has a market cap of 18.1B. Regarding current trading prices, IDYA is priced at $32.60, while INCY trades at $92.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas INCY's P/E ratio is 14.16. In terms of profitability, IDYA's ROE is -0.11%, compared to INCY's ROE of +0.29%. Regarding short-term risk, IDYA is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check INCY's competition here
IDYA vs GMAB Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, GMAB has a market cap of 15.5B. Regarding current trading prices, IDYA is priced at $32.60, while GMAB trades at $25.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas GMAB's P/E ratio is 16.30. In terms of profitability, IDYA's ROE is -0.11%, compared to GMAB's ROE of +0.11%. Regarding short-term risk, IDYA is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check GMAB's competition here
IDYA vs ASND Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, ASND has a market cap of 13.6B. Regarding current trading prices, IDYA is priced at $32.60, while ASND trades at $223.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas ASND's P/E ratio is -51.49. In terms of profitability, IDYA's ROE is -0.11%, compared to ASND's ROE of +1.28%. Regarding short-term risk, IDYA is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check ASND's competition here
IDYA vs BBIO Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, BBIO has a market cap of 13.3B. Regarding current trading prices, IDYA is priced at $32.60, while BBIO trades at $70.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas BBIO's P/E ratio is -18.14. In terms of profitability, IDYA's ROE is -0.11%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, IDYA is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check BBIO's competition here
IDYA vs KRTX Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, IDYA is priced at $32.60, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas KRTX's P/E ratio is -28.09. In terms of profitability, IDYA's ROE is -0.11%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, IDYA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check KRTX's competition here
IDYA vs IONS Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, IONS has a market cap of 11.7B. Regarding current trading prices, IDYA is priced at $32.60, while IONS trades at $71.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas IONS's P/E ratio is -29.83. In terms of profitability, IDYA's ROE is -0.11%, compared to IONS's ROE of -0.69%. Regarding short-term risk, IDYA is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check IONS's competition here
IDYA vs SMMT Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, SMMT has a market cap of 11.5B. Regarding current trading prices, IDYA is priced at $32.60, while SMMT trades at $15.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas SMMT's P/E ratio is -10.77. In terms of profitability, IDYA's ROE is -0.11%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, IDYA is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check SMMT's competition here
IDYA vs RNAM Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, IDYA is priced at $32.60, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas RNAM's P/E ratio is -17.39. In terms of profitability, IDYA's ROE is -0.11%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, IDYA is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check RNAM's competition here
IDYA vs JAZZ Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, JAZZ has a market cap of 11.1B. Regarding current trading prices, IDYA is priced at $32.60, while JAZZ trades at $181.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas JAZZ's P/E ratio is -30.88. In terms of profitability, IDYA's ROE is -0.11%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, IDYA is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check JAZZ's competition here
IDYA vs EXEL Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, EXEL has a market cap of 11.1B. Regarding current trading prices, IDYA is priced at $32.60, while EXEL trades at $41.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas EXEL's P/E ratio is 14.59. In terms of profitability, IDYA's ROE is -0.11%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, IDYA is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check EXEL's competition here
IDYA vs BMRN Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, BMRN has a market cap of 10.4B. Regarding current trading prices, IDYA is priced at $32.60, while BMRN trades at $55.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas BMRN's P/E ratio is 30.09. In terms of profitability, IDYA's ROE is -0.11%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, IDYA is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check BMRN's competition here
IDYA vs MDGL Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, MDGL has a market cap of 10.1B. Regarding current trading prices, IDYA is priced at $32.60, while MDGL trades at $454.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas MDGL's P/E ratio is -34.30. In terms of profitability, IDYA's ROE is -0.11%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, IDYA is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check MDGL's competition here
IDYA vs RXDX Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, IDYA is priced at $32.60, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas RXDX's P/E ratio is -56.47. In terms of profitability, IDYA's ROE is -0.11%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, IDYA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check RXDX's competition here
IDYA vs IMGN Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, IDYA is priced at $32.60, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas IMGN's P/E ratio is -111.55. In terms of profitability, IDYA's ROE is -0.11%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, IDYA is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check IMGN's competition here
IDYA vs IBRX Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, IBRX has a market cap of 8.7B. Regarding current trading prices, IDYA is priced at $32.60, while IBRX trades at $8.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas IBRX's P/E ratio is -22.29. In terms of profitability, IDYA's ROE is -0.11%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, IDYA is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check IBRX's competition here
IDYA vs BPMC Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, IDYA is priced at $32.60, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas BPMC's P/E ratio is -51.58. In terms of profitability, IDYA's ROE is -0.11%, compared to BPMC's ROE of -0.33%. Regarding short-term risk, IDYA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check BPMC's competition here
IDYA vs CERE Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, IDYA is priced at $32.60, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas CERE's P/E ratio is -16.47. In terms of profitability, IDYA's ROE is -0.11%, compared to CERE's ROE of -0.72%. Regarding short-term risk, IDYA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check CERE's competition here
IDYA vs TECH Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, TECH has a market cap of 8.1B. Regarding current trading prices, IDYA is priced at $32.60, while TECH trades at $51.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas TECH's P/E ratio is 97.13. In terms of profitability, IDYA's ROE is -0.11%, compared to TECH's ROE of +0.04%. Regarding short-term risk, IDYA is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check TECH's competition here
IDYA vs AXSM Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, AXSM has a market cap of 8B. Regarding current trading prices, IDYA is priced at $32.60, while AXSM trades at $158.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas AXSM's P/E ratio is -42.76. In terms of profitability, IDYA's ROE is -0.11%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, IDYA is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check AXSM's competition here
IDYA vs ABVX Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, ABVX has a market cap of 7.9B. Regarding current trading prices, IDYA is priced at $32.60, while ABVX trades at $123.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas ABVX's P/E ratio is -23.48. In terms of profitability, IDYA's ROE is -0.11%, compared to ABVX's ROE of +50.78%. Regarding short-term risk, IDYA is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check ABVX's competition here
IDYA vs ARWR Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, ARWR has a market cap of 7.9B. Regarding current trading prices, IDYA is priced at $32.60, while ARWR trades at $56.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas ARWR's P/E ratio is 35.19. In terms of profitability, IDYA's ROE is -0.11%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, IDYA is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check ARWR's competition here
IDYA vs PCVX Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, PCVX has a market cap of 7.9B. Regarding current trading prices, IDYA is priced at $32.60, while PCVX trades at $53.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas PCVX's P/E ratio is -9.72. In terms of profitability, IDYA's ROE is -0.11%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, IDYA is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check PCVX's competition here
IDYA vs CYTK Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, CYTK has a market cap of 7.6B. Regarding current trading prices, IDYA is priced at $32.60, while CYTK trades at $62.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas CYTK's P/E ratio is -9.43. In terms of profitability, IDYA's ROE is -0.11%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, IDYA is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check CYTK's competition here
IDYA vs HALO Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, HALO has a market cap of 7.5B. Regarding current trading prices, IDYA is priced at $32.60, while HALO trades at $63.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas HALO's P/E ratio is 24.78. In terms of profitability, IDYA's ROE is -0.11%, compared to HALO's ROE of +0.93%. Regarding short-term risk, IDYA is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check HALO's competition here
IDYA vs MTSR Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, IDYA is priced at $32.60, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas MTSR's P/E ratio is -23.58. In terms of profitability, IDYA's ROE is -0.11%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, IDYA is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check MTSR's competition here
IDYA vs KRYS Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, KRYS has a market cap of 7.4B. Regarding current trading prices, IDYA is priced at $32.60, while KRYS trades at $258.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas KRYS's P/E ratio is 36.80. In terms of profitability, IDYA's ROE is -0.11%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, IDYA is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check KRYS's competition here
IDYA vs NUVL Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, NUVL has a market cap of 6.9B. Regarding current trading prices, IDYA is priced at $32.60, while NUVL trades at $97.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas NUVL's P/E ratio is -16.20. In terms of profitability, IDYA's ROE is -0.11%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, IDYA is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check NUVL's competition here
IDYA vs MRUS Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, IDYA is priced at $32.60, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas MRUS's P/E ratio is -17.05. In terms of profitability, IDYA's ROE is -0.11%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, IDYA is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check MRUS's competition here
IDYA vs ACLX Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, IDYA is priced at $32.60, while ACLX trades at $114.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas ACLX's P/E ratio is -28.21. In terms of profitability, IDYA's ROE is -0.11%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, IDYA is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check ACLX's competition here
IDYA vs RETA Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, IDYA is priced at $32.60, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas RETA's P/E ratio is -66.29. In terms of profitability, IDYA's ROE is -0.11%, compared to RETA's ROE of +0.47%. Regarding short-term risk, IDYA is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check RETA's competition here
IDYA vs KYMR Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, KYMR has a market cap of 6.4B. Regarding current trading prices, IDYA is priced at $32.60, while KYMR trades at $79.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas KYMR's P/E ratio is -21.11. In terms of profitability, IDYA's ROE is -0.11%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, IDYA is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check KYMR's competition here
IDYA vs PTGX Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, PTGX has a market cap of 6.3B. Regarding current trading prices, IDYA is priced at $32.60, while PTGX trades at $101.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas PTGX's P/E ratio is -48.23. In terms of profitability, IDYA's ROE is -0.11%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, IDYA is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check PTGX's competition here
IDYA vs PRAX Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, PRAX has a market cap of 6.3B. Regarding current trading prices, IDYA is priced at $32.60, while PRAX trades at $297.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas PRAX's P/E ratio is -22.15. In terms of profitability, IDYA's ROE is -0.11%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, IDYA is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check PRAX's competition here
IDYA vs BLTE Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, BLTE has a market cap of 6.1B. Regarding current trading prices, IDYA is priced at $32.60, while BLTE trades at $159.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas BLTE's P/E ratio is -67.01. In terms of profitability, IDYA's ROE is -0.11%, compared to BLTE's ROE of -0.43%. Regarding short-term risk, IDYA is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check BLTE's competition here
IDYA vs RYTM Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, RYTM has a market cap of 6B. Regarding current trading prices, IDYA is priced at $32.60, while RYTM trades at $90.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas RYTM's P/E ratio is -28.12. In terms of profitability, IDYA's ROE is -0.11%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, IDYA is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check RYTM's competition here
IDYA vs CDTX Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, IDYA is priced at $32.60, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas CDTX's P/E ratio is -19.77. In terms of profitability, IDYA's ROE is -0.11%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, IDYA is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check CDTX's competition here
IDYA vs ABCM Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, IDYA is priced at $32.60, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, IDYA's ROE is -0.11%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, IDYA is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check ABCM's competition here
IDYA vs ISEE Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, IDYA is priced at $32.60, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas ISEE's P/E ratio is -22.44. In terms of profitability, IDYA's ROE is -0.11%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, IDYA is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check ISEE's competition here
IDYA vs CGON Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, CGON has a market cap of 5.5B. Regarding current trading prices, IDYA is priced at $32.60, while CGON trades at $65.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas CGON's P/E ratio is -31.28. In terms of profitability, IDYA's ROE is -0.11%, compared to CGON's ROE of -0.23%. Regarding short-term risk, IDYA is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check CGON's competition here
IDYA vs COGT Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, COGT has a market cap of 5.4B. Regarding current trading prices, IDYA is priced at $32.60, while COGT trades at $34.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas COGT's P/E ratio is -15.45. In terms of profitability, IDYA's ROE is -0.11%, compared to COGT's ROE of -1.00%. Regarding short-term risk, IDYA is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check COGT's competition here
IDYA vs PTCT Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, PTCT has a market cap of 5.4B. Regarding current trading prices, IDYA is priced at $32.60, while PTCT trades at $67.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas PTCT's P/E ratio is 7.61. In terms of profitability, IDYA's ROE is -0.11%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, IDYA is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check PTCT's competition here
IDYA vs FBIOX Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, FBIOX has a market cap of 5.4B. Regarding current trading prices, IDYA is priced at $32.60, while FBIOX trades at $24.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas FBIOX's P/E ratio is N/A. In terms of profitability, IDYA's ROE is -0.11%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, IDYA is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check FBIOX's competition here
IDYA vs CAI Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, CAI has a market cap of 5.2B. Regarding current trading prices, IDYA is priced at $32.60, while CAI trades at $18.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas CAI's P/E ratio is -5.72. In terms of profitability, IDYA's ROE is -0.11%, compared to CAI's ROE of +0.25%. Regarding short-term risk, IDYA is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check CAI's competition here
IDYA vs SRRK Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, SRRK has a market cap of 5.1B. Regarding current trading prices, IDYA is priced at $32.60, while SRRK trades at $45.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas SRRK's P/E ratio is -13.57. In terms of profitability, IDYA's ROE is -0.11%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, IDYA is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check SRRK's competition here
IDYA vs CELC Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, CELC has a market cap of 4.9B. Regarding current trading prices, IDYA is priced at $32.60, while CELC trades at $112.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas CELC's P/E ratio is -28.86. In terms of profitability, IDYA's ROE is -0.11%, compared to CELC's ROE of -1.79%. Regarding short-term risk, IDYA is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check CELC's competition here
IDYA vs TGTX Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, TGTX has a market cap of 4.8B. Regarding current trading prices, IDYA is priced at $32.60, while TGTX trades at $30.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas TGTX's P/E ratio is 9.93. In terms of profitability, IDYA's ROE is -0.11%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, IDYA is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check TGTX's competition here
IDYA vs ALKS Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, ALKS has a market cap of 4.7B. Regarding current trading prices, IDYA is priced at $32.60, while ALKS trades at $28.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas ALKS's P/E ratio is 19.70. In terms of profitability, IDYA's ROE is -0.11%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, IDYA is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check ALKS's competition here
IDYA vs IMVT Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, IMVT has a market cap of 4.7B. Regarding current trading prices, IDYA is priced at $32.60, while IMVT trades at $23.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas IMVT's P/E ratio is -8.61. In terms of profitability, IDYA's ROE is -0.11%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, IDYA is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check IMVT's competition here
IDYA vs XENE Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, XENE has a market cap of 4.6B. Regarding current trading prices, IDYA is priced at $32.60, while XENE trades at $55.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas XENE's P/E ratio is -12.60. In terms of profitability, IDYA's ROE is -0.11%, compared to XENE's ROE of -0.56%. Regarding short-term risk, IDYA is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check XENE's competition here
IDYA vs ERAS Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, ERAS has a market cap of 4.5B. Regarding current trading prices, IDYA is priced at $32.60, while ERAS trades at $15.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas ERAS's P/E ratio is -33.18. In terms of profitability, IDYA's ROE is -0.11%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, IDYA is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check ERAS's competition here
IDYA vs FOLD Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, IDYA is priced at $32.60, while FOLD trades at $14.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas FOLD's P/E ratio is -160.06. In terms of profitability, IDYA's ROE is -0.11%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, IDYA is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check FOLD's competition here
IDYA vs AKRO Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, IDYA is priced at $32.60, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas AKRO's P/E ratio is -14.57. In terms of profitability, IDYA's ROE is -0.11%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, IDYA is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check AKRO's competition here
IDYA vs ALPN Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, IDYA is priced at $32.60, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas ALPN's P/E ratio is -101.52. In terms of profitability, IDYA's ROE is -0.11%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, IDYA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check ALPN's competition here
IDYA vs MIRM Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, MIRM has a market cap of 4.4B. Regarding current trading prices, IDYA is priced at $32.60, while MIRM trades at $90.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas MIRM's P/E ratio is -188.36. In terms of profitability, IDYA's ROE is -0.11%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, IDYA is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check MIRM's competition here
IDYA vs CRSP Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, CRSP has a market cap of 4.4B. Regarding current trading prices, IDYA is priced at $32.60, while CRSP trades at $46.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas CRSP's P/E ratio is -7.15. In terms of profitability, IDYA's ROE is -0.11%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, IDYA is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check CRSP's competition here
IDYA vs TERN Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, TERN has a market cap of 4.4B. Regarding current trading prices, IDYA is priced at $32.60, while TERN trades at $49.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas TERN's P/E ratio is -47.49. In terms of profitability, IDYA's ROE is -0.11%, compared to TERN's ROE of -0.30%. Regarding short-term risk, IDYA is less volatile compared to TERN. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check TERN's competition here
IDYA vs OPT Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, IDYA is priced at $32.60, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas OPT's P/E ratio is -1.52. In terms of profitability, IDYA's ROE is -0.11%, compared to OPT's ROE of +0.88%. Regarding short-term risk, IDYA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check OPT's competition here
IDYA vs MRTX Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, IDYA is priced at $32.60, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas MRTX's P/E ratio is -4.82. In terms of profitability, IDYA's ROE is -0.11%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, IDYA is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check MRTX's competition here
IDYA vs LGND Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, LGND has a market cap of 4.1B. Regarding current trading prices, IDYA is priced at $32.60, while LGND trades at $210.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas LGND's P/E ratio is 33.47. In terms of profitability, IDYA's ROE is -0.11%, compared to LGND's ROE of +0.14%. Regarding short-term risk, IDYA is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check LGND's competition here
IDYA vs RYZB Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, IDYA is priced at $32.60, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas RYZB's P/E ratio is -57.86. In terms of profitability, IDYA's ROE is -0.11%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, IDYA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check RYZB's competition here
IDYA vs VKTX Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, IDYA is priced at $32.60, while VKTX trades at $33.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas VKTX's P/E ratio is -10.13. In terms of profitability, IDYA's ROE is -0.11%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, IDYA is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check VKTX's competition here
IDYA vs CBAY Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, IDYA is priced at $32.60, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas CBAY's P/E ratio is -32.81. In terms of profitability, IDYA's ROE is -0.11%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, IDYA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check CBAY's competition here
IDYA vs CRNX Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, CRNX has a market cap of 3.7B. Regarding current trading prices, IDYA is priced at $32.60, while CRNX trades at $35.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas CRNX's P/E ratio is -7.19. In terms of profitability, IDYA's ROE is -0.11%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, IDYA is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check CRNX's competition here
IDYA vs CORT Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, CORT has a market cap of 3.7B. Regarding current trading prices, IDYA is priced at $32.60, while CORT trades at $34.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas CORT's P/E ratio is 42.26. In terms of profitability, IDYA's ROE is -0.11%, compared to CORT's ROE of +0.15%. Regarding short-term risk, IDYA is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check CORT's competition here
IDYA vs APGE Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, APGE has a market cap of 3.7B. Regarding current trading prices, IDYA is priced at $32.60, while APGE trades at $68.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas APGE's P/E ratio is -15.65. In terms of profitability, IDYA's ROE is -0.11%, compared to APGE's ROE of -0.37%. Regarding short-term risk, IDYA is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check APGE's competition here
IDYA vs CNTA Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, CNTA has a market cap of 3.6B. Regarding current trading prices, IDYA is priced at $32.60, while CNTA trades at $28.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas CNTA's P/E ratio is -14.33. In terms of profitability, IDYA's ROE is -0.11%, compared to CNTA's ROE of -0.68%. Regarding short-term risk, IDYA is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check CNTA's competition here
IDYA vs SWTX Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, IDYA is priced at $32.60, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas SWTX's P/E ratio is -13.78. In terms of profitability, IDYA's ROE is -0.11%, compared to SWTX's ROE of -0.45%. Regarding short-term risk, IDYA is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check SWTX's competition here
IDYA vs ACAD Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, ACAD has a market cap of 3.5B. Regarding current trading prices, IDYA is priced at $32.60, while ACAD trades at $20.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas ACAD's P/E ratio is 9.02. In terms of profitability, IDYA's ROE is -0.11%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, IDYA is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check ACAD's competition here
IDYA vs KNSA Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, KNSA has a market cap of 3.4B. Regarding current trading prices, IDYA is priced at $32.60, while KNSA trades at $45.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas KNSA's P/E ratio is 61.44. In terms of profitability, IDYA's ROE is -0.11%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, IDYA is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check KNSA's competition here
IDYA vs ADMA Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, ADMA has a market cap of 3.4B. Regarding current trading prices, IDYA is priced at $32.60, while ADMA trades at $15.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas ADMA's P/E ratio is 23.87. In terms of profitability, IDYA's ROE is -0.11%, compared to ADMA's ROE of +0.35%. Regarding short-term risk, IDYA is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check ADMA's competition here
IDYA vs NAMS Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, NAMS has a market cap of 3.3B. Regarding current trading prices, IDYA is priced at $32.60, while NAMS trades at $30.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas NAMS's P/E ratio is -16.83. In terms of profitability, IDYA's ROE is -0.11%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, IDYA is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check NAMS's competition here
IDYA vs LQDA Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, LQDA has a market cap of 3.2B. Regarding current trading prices, IDYA is priced at $32.60, while LQDA trades at $37.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas LQDA's P/E ratio is -45.49. In terms of profitability, IDYA's ROE is -0.11%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, IDYA is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check LQDA's competition here
IDYA vs DNLI Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, DNLI has a market cap of 3.2B. Regarding current trading prices, IDYA is priced at $32.60, while DNLI trades at $19.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas DNLI's P/E ratio is -6.80. In terms of profitability, IDYA's ROE is -0.11%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, IDYA is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check DNLI's competition here
IDYA vs EWTX Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, EWTX has a market cap of 3.1B. Regarding current trading prices, IDYA is priced at $32.60, while EWTX trades at $30.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas EWTX's P/E ratio is -17.82. In terms of profitability, IDYA's ROE is -0.11%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, IDYA is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check EWTX's competition here
IDYA vs TLX Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, TLX has a market cap of 3B. Regarding current trading prices, IDYA is priced at $32.60, while TLX trades at $8.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas TLX's P/E ratio is -437.50. In terms of profitability, IDYA's ROE is -0.11%, compared to TLX's ROE of -0.02%. Regarding short-term risk, IDYA is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check TLX's competition here
IDYA vs DYN Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, DYN has a market cap of 2.9B. Regarding current trading prices, IDYA is priced at $32.60, while DYN trades at $17.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas DYN's P/E ratio is -5.06. In terms of profitability, IDYA's ROE is -0.11%, compared to DYN's ROE of -0.61%. Regarding short-term risk, IDYA is less volatile compared to DYN. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check DYN's competition here
IDYA vs VERA Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, VERA has a market cap of 2.9B. Regarding current trading prices, IDYA is priced at $32.60, while VERA trades at $41.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas VERA's P/E ratio is -8.70. In terms of profitability, IDYA's ROE is -0.11%, compared to VERA's ROE of -0.60%. Regarding short-term risk, IDYA is less volatile compared to VERA. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check VERA's competition here
IDYA vs MORF Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, IDYA is priced at $32.60, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas MORF's P/E ratio is -14.88. In terms of profitability, IDYA's ROE is -0.11%, compared to MORF's ROE of -0.29%. Regarding short-term risk, IDYA is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check MORF's competition here
IDYA vs MOR Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, IDYA is priced at $32.60, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas MOR's P/E ratio is -12.64. In terms of profitability, IDYA's ROE is -0.11%, compared to MOR's ROE of -1.84%. Regarding short-term risk, IDYA is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check MOR's competition here
IDYA vs DNTH Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, DNTH has a market cap of 2.8B. Regarding current trading prices, IDYA is priced at $32.60, while DNTH trades at $80.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas DNTH's P/E ratio is -22.24. In terms of profitability, IDYA's ROE is -0.11%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, IDYA is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check DNTH's competition here
IDYA vs CPRX Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, CPRX has a market cap of 2.8B. Regarding current trading prices, IDYA is priced at $32.60, while CPRX trades at $22.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas CPRX's P/E ratio is 13.57. In terms of profitability, IDYA's ROE is -0.11%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, IDYA is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check CPRX's competition here
IDYA vs GPCR Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, GPCR has a market cap of 2.8B. Regarding current trading prices, IDYA is priced at $32.60, while GPCR trades at $50.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas GPCR's P/E ratio is -20.25. In terms of profitability, IDYA's ROE is -0.11%, compared to GPCR's ROE of -0.15%. Regarding short-term risk, IDYA is less volatile compared to GPCR. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check GPCR's competition here
IDYA vs ARQT Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, ARQT has a market cap of 2.8B. Regarding current trading prices, IDYA is priced at $32.60, while ARQT trades at $22.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas ARQT's P/E ratio is -171.08. In terms of profitability, IDYA's ROE is -0.11%, compared to ARQT's ROE of -0.10%. Regarding short-term risk, IDYA is less volatile compared to ARQT. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check ARQT's competition here
IDYA vs TARS Comparison March 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, TARS has a market cap of 2.7B. Regarding current trading prices, IDYA is priced at $32.60, while TARS trades at $66.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.59, whereas TARS's P/E ratio is -40.57. In terms of profitability, IDYA's ROE is -0.11%, compared to TARS's ROE of -0.20%. Regarding short-term risk, IDYA is more volatile compared to TARS. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check TARS's competition here